Director's Updates about Clinical Research And Trials

NIMH Perspective on Antipsychotic Reimbursement: Using Results from the CATIE Cost Effectiveness Study

December 1, 2006 • Director's Update
The recent publication (December 1, 2006, American Journal of Psychiatry) of the cost-effectiveness results from the National Institute of Mental Health (NIMH)-funded Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) has raised questions among advocates, families, and clinicians about reimbursement policies for antipsychotic medications.

NIMH Perspective on Treating Alzheimer’s Patients with Antipsychotic Medications

October 12, 2006 • Director's Update
The recent publication of phase 1 results from the NIMH-funded Clinical Antipsychotic Trials in Intervention Effectiveness for Alzheimer's disease (CATIE-AD) in the New England Journal of Medicine provides new information about the use of several “atypical” antipsychotic medications for the treatment of psychotic symptoms in patients with Alzheimer's disease.

Footer

Some NIMH pages link to PDF files. Download Adobe Reader to view and print PDF files.

The National Institute of Mental Health (NIMH) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services.